Plain-English translation of NCT06387810 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new chemotherapy combination called Irinotecan Liposome II, used together with two other chemotherapy drugs (5-FU/LV and oxaliplatin), to treat borderline resectable pancreatic cancer—a type of cancer that is difficult but potentially possible to surgically remove. The medication is given before surgery to try to shrink the tumor and make it easier to remove, and again after surgery to help prevent the cancer from coming back.
Pancreatic cancer that is on the borderline of being removable has a poor outlook with standard treatment. Researchers are testing whether this new medication combination, given before and after surgery, can improve outcomes and help more patients survive longer.
If you join this trial, you will receive 4 rounds of chemotherapy (the medication combination) over about 8 weeks before surgery, with treatments given every 2 weeks. After surgery (which will occur 2 to 4 weeks later), you will receive 4 more rounds of the same chemotherapy over another 8 weeks. Your doctors will then monitor you closely with imaging scans and follow-up visits to watch for any signs of cancer returning.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China